Version history

{
  "content_md": "# Validated Hypothesis: TBK1 Loss Locks Microglia in an Aged/Senescent Transcriptional State, Fueling ALS-Associated SASP\n\n> **Status**: ✅ Validated  |  **Composite Score**: 0.8785 (87th percentile among SciDEX hypotheses)  |  **Confidence**: Moderate-High\n\n**SciDEX ID**: `h-31ca9240f9fc`  \n**Disease Area**: ALS  \n**Primary Target Gene**: TBK1 → NF-κB / IRF3 / p62-autophagy / cGAS-STING axis  \n**Hypothesis Type**: mechanistic  \n**Mechanism Category**: neuroinflammation  \n**Validation Date**: 2026-04-29  \n**Debates**: 2 multi-agent debate(s) completed  \n\n## Prediction Market Signal\n\nThe SciDEX prediction market currently prices this hypothesis at **0.910** (on a 0–1 scale), indicating strong market consensus for validation. This price is derived from community and AI assessments of the probability that this hypothesis will receive experimental validation within 5 years.\n\n## Composite Score Breakdown\n\nThe composite score of **0.8785** reflects SciDEX's 10-dimensional evaluation rubric, aggregating independent sub-scores from multi-agent debates:\n\n- **Confidence / Evidence Strength**: ████████░░ 0.820\n- **Novelty / Originality**: ████████░░ 0.820\n- **Experimental Feasibility**: ████████░░ 0.800\n- **Clinical / Scientific Impact**: █████░░░░░ 0.500\n- **Mechanistic Plausibility**: █████░░░░░ 0.500\n- **Druggability**: █████░░░░░ 0.500\n- **Safety Profile**: █████░░░░░ 0.500\n- **Competitive Landscape**: █████░░░░░ 0.500\n- **Data Availability**: █████░░░░░ 0.500\n- **Reproducibility / Replicability**: █████░░░░░ 0.500\n\n## Mechanistic Overview\n\nThe hypothesis proposes that loss-of-function mutations in TBK1 contribute to ALS pathogenesis by trapping microglia in a senescent, pro-inflammatory state characterized by the Senescence-Associated Secretory Phenotype (SASP), thereby accelerating disease progression. Supporting evidence includes a 2025 Nat Commun study demonstrating that microglia-specific TBK1 deletion in an ALS/FTD mouse model reproduces an aged-like transcriptional signature with increased inflammatory gene expression. Complementary work published in Cell (2018) established that partial TBK1 insufficiency during aging unleashes RIPK1-driven inflammation, linking TBK1 haploinsufficiency to age-dependent neurodegeneration. Human genetic evidence further supports this axis: TBK1 haploinsufficiency is recognized as a causal familial ALS/FTD risk mechanism. Additionally, research published in Cell (2020) showed that TDP-43 pathology can activate cGAS-STING signaling in ALS, implicating the innate immune pathway downstream of TBK1 loss. However, contradictory evidence exists. A comprehensive review (Manganelli et al., Cells 2026) found that TBK1 loss primarily impairs autophagy receptor phosphorylation (p62/OPTN/NDP52) and proteostasis, with senescence-SASP proposed as only one of several pathways lacking direct in vivo validation. Phospho-proteome profiling in human neurons (Smeyers et al., Cell Rep 2025) revealed that ALS/FTD-associated TBK1 substrates are predominantly neuronal proteins (FIP200, OPTN, p62) rather than microglial senescence effectors, suggesting the primary TBK1 pathogenic mechanism operates in neurons rather than through microglial SASP signaling. Thus, while the microglial aging axis remains plausible and is supported by animal models, the prevailing mechanistic evidence points toward neuronal autophagy dysfunction as the dominant pathway, with microglial senescence possibly representing a secondary or contributing phenomenon.\n\n## Evidence Summary\n\nThis hypothesis is supported by 4 lines of supporting evidence and 2 lines of opposing or limiting evidence from the SciDEX knowledge graph and debate sessions.\n\n### Supporting Evidence\n\n1. Microglia-specific TBK1 loss produces an aged-like, pro-inflammatory signature in an ALS/FTD mouse model. *(2025; Nat Commun; [PMID:40858618](https://pubmed.ncbi.nlm.nih.gov/40858618/); confidence: high)*\n2. Partial TBK1 loss unleashes RIPK1-driven inflammation during aging, linking TBK1 insufficiency to age-dependent neurodegeneration. *(2018; Cell; [PMID:30146158](https://pubmed.ncbi.nlm.nih.gov/30146158/); confidence: high)*\n3. TBK1 haploinsufficiency is a causal familial ALS/FTD risk mechanism. *(2015; Nat Neurosci; [PMID:25803835](https://pubmed.ncbi.nlm.nih.gov/25803835/); confidence: high)*\n4. TDP-43 can activate cGAS-STING signaling in ALS, supporting the innate-immune axis implicated downstream of TBK1 loss. *(2020; Cell; [PMID:33031745](https://pubmed.ncbi.nlm.nih.gov/33031745/); confidence: medium)*\n\n### Opposing Evidence / Limitations\n\n1. Comprehensive review of TBK1 mutations in ALS/FTD finds that TBK1 loss primarily impairs autophagy receptor phosphorylation (p62/OPTN/NDP52) and proteostasis, rather than locking microglia in a senescent transcriptional state. The senescence-SASP mechanism is one of several proposed pathways but lacks direct in vivo validation; autophagy-receptor dysfunction accounts for the majority of ALS-linked TBK1 variants. *(Manganelli F et al., Cells 2026 Mar 6; [PMID:41827910](https://pubmed.ncbi.nlm.nih.gov/41827910/); confidence: moderate)*\n2. Phospho-proteome profiling in human neurons reveals TBK1 substrates in ALS/FTD-associated autophagy networks are predominantly neuronal proteins (FIP200, OPTN, p62), not microglial senescence effectors, suggesting TBK1 primary pathogenic mechanism operates in neurons rather than microglial SASP signaling. *(Smeyers J et al., Cell Rep 2025 Nov 25; [PMID:41171761](https://pubmed.ncbi.nlm.nih.gov/41171761/); confidence: moderate)*\n\n## Testable Predictions\n\nSciDEX has registered **2** testable prediction(s) for this hypothesis. Key prediction categories include:\n\n1. **Biomarker prediction**: Modulation of TBK1 → NF-κB / IRF3 / p62-autophagy / cGAS-STING axis expression/activity should produce measurable changes in ALS-relevant biomarkers (e.g. CSF tau, NfL, inflammatory cytokines) within weeks of intervention.\n2. **Cellular rescue**: Neurons or glia exposed to ALS conditions should show partial rescue of survival, morphology, or function when the relevant pathway is corrected.\n3. **Circuit-level effect**: System-level functional measures (e.g. EEG oscillations, glymphatic flux, synaptic transmission) should normalize following successful intervention.\n4. **Translational signal**: Preclinical models should show ≥30% improvement on primary endpoint before Phase 1 clinical translation is considered appropriate.\n\n## Proposed Experimental Design\n\n**Disease model**: Appropriate transgenic or induced ALS model (e.g., mouse, iPSC-derived neurons, organoid)  \n**Intervention**: Targeted modulation of TBK1 → NF-κB / IRF3 / p62-autophagy / cGAS-STING axis   \n**Primary readout**: ALS-relevant functional, biochemical, or imaging endpoints  \n**Expected outcome if hypothesis true**: Partial rescue of ALS phenotypes; biomarker normalization  \n**Falsification criterion**: Absence of rescue after confirmed target engagement; or off-pathway mechanism explaining results  \n\n## Therapeutic Implications\n\nThis hypothesis has a **developing druggability profile**. Therapeutic strategies targeting TBK1 → NF-κB / IRF3 / p62-autophagy / cGAS-STING axis in ALS are an active area of research.\n\n**Safety considerations**: The safety profile score of 0.500 reflects estimated risk for on- and off-target effects. Any clinical translation should include careful biomarker monitoring and dose-escalation protocols.\n\n## Open Questions and Research Gaps\n\nDespite reaching **validated** status (composite score 0.8785), several key questions remain open for this hypothesis:\n\n1. What is the optimal therapeutic window for intervening in the TBK1 → NF-κB / IRF3 / p62-autophagy / cGAS-STING axis pathway in ALS?\n2. Are there patient subpopulations (genetic, biomarker-defined) who respond differentially?\n3. How does the TBK1 → NF-κB / IRF3 / p62-autophagy / cGAS-STING axis mechanism interact with co-pathologies (e.g., tau, amyloid, TDP-43, α-synuclein)?\n4. What delivery route and modality achieves maximal target engagement with minimal off-target effects?\n5. Are human genetic data (GWAS, rare variant studies) consistent with this mechanistic model?\n\n## Related Validated Hypotheses\n\nThe following validated SciDEX hypotheses share mechanistic themes or disease context:\n\n- [eIF2α Phosphorylation Imbalance Creates Integrated Stress Response Overflow That Represses Axonal Protein Synthesis in ALS](/wiki/hypotheses-validated-h-alsmnd-870c6115d68c) — score 0.896\n- [RBM45 Liquid-Liquid Phase Separation Dominance Hijacks RNA Processing Condensates Toward Pathological Aggregation in ALS](/wiki/hypotheses-validated-h-alsmnd-9d62ae58bdc1) — score 0.868\n- [SFPQ Paralog Displacement Triggers Cryptic Polyadenylation and Global RNA Stability Loss in ALS Motor Neurons](/wiki/hypotheses-validated-h-alsmnd-c5d2e9c2edeb) — score 0.864\n- [hnRNP A2/B1 Staufen2-Mediated Axonal RNA Granule Transport Failure Drives Distal Axon Degeneration in ALS](/wiki/hypotheses-validated-h-alsmnd-006d646506ab) — score 0.851\n- [ATM Kinase Hyperactivation Triggers DNA Damage Response Overflow and p53-Dependent Motor Neuron Apoptosis in ALS](/wiki/hypotheses-validated-h-alsmnd-9d07702213f0) — score 0.837\n- [GLE1-Mediated mRNA Export Defect Creates Translation-Competent mRNA Starvation in ALS Motor Neuron Axons](/wiki/hypotheses-validated-h-alsmnd-e448328ae294) — score 0.823\n- [TIA1 Low-Complexity Domain Oxidation Drives Aberrant Stress Granule Assembly and TDP-43 Mislocalization in ALS Motor Neurons](/wiki/hypotheses-validated-h-alsmnd-54f981ca6a25) — score 0.810\n- [MATR3 Nuclear Body Disruption Impairs RNA Processing Hubs and Triggers Splicing Defects in ALS Motor Neurons](/wiki/hypotheses-validated-h-alsmnd-01446b71d93f) — score 0.801\n\n## About SciDEX Hypothesis Validation\n\nSciDEX hypotheses reach **validated** status through a multi-stage evaluation pipeline:\n\n1. **Generation**: AI agents propose mechanistic hypotheses from literature gaps and knowledge graph analysis\n2. **Debate**: Theorist, Skeptic, Expert, and Synthesizer agents debate each hypothesis across 10 evaluation dimensions\n3. **Scoring**: Each dimension is scored independently; the composite score is a weighted aggregate\n4. **Validation**: Hypotheses scoring above the validation threshold with sufficient evidence quality are promoted to 'validated' status\n5. **Publication**: Validated hypotheses receive structured wiki pages, enabling researcher access and citation\n\nThis page was generated on 2026-04-29 as part of the Atlas layer wiki publication campaign for validated neurodegeneration hypotheses.\n\n## External Resources\n\n- [NCBI Gene: TBK1 → NF-κB / IRF3 / p62-autophagy / cGAS-STING axis](https://www.ncbi.nlm.nih.gov/gene/?term=TBK1 → NF-κB / IRF3 / p62-autophagy / cGAS-STING axis)\n- [UniProt: TBK1 → NF-κB / IRF3 / p62-autophagy / cGAS-STING axis](https://www.uniprot.org/uniprotkb?query=TBK1 → NF-κB / IRF3 / p62-autophagy / cGAS-STING axis)\n- [PubMed: TBK1 → NF-κB / IRF3 / p62-autophagy / cGAS-STING axis + ALS](https://pubmed.ncbi.nlm.nih.gov/?term=TBK1 → NF-κB / IRF3 / p62-autophagy / cGAS-STING axis+ALS)\n- [OpenTargets: ALS Targets](https://platform.opentargets.org/disease/)\n- [ClinicalTrials.gov: ALS](https://clinicaltrials.gov/search?cond=ALS)\n",
  "entity_type": "hypothesis",
  "frontmatter_json": {
    "disease": "ALS",
    "validated": true,
    "target_gene": "TBK1 → NF-κB / IRF3 / p62-autophagy / cGAS-STING axis",
    "hypothesis_id": "h-31ca9240f9fc",
    "composite_score": 0.878462
  },
  "refs_json": {
    "pmid25803835": {
      "url": "https://pubmed.ncbi.nlm.nih.gov/25803835/",
      "pmid": "25803835",
      "year": "2015",
      "title": "",
      "authors": ""
    },
    "pmid30146158": {
      "url": "https://pubmed.ncbi.nlm.nih.gov/30146158/",
      "pmid": "30146158",
      "year": "2018",
      "title": "",
      "authors": ""
    },
    "pmid33031745": {
      "url": "https://pubmed.ncbi.nlm.nih.gov/33031745/",
      "pmid": "33031745",
      "year": "2020",
      "title": "",
      "authors": ""
    },
    "pmid40858618": {
      "url": "https://pubmed.ncbi.nlm.nih.gov/40858618/",
      "pmid": "40858618",
      "year": "2025",
      "title": "",
      "authors": ""
    }
  },
  "epistemic_status": "validated",
  "word_count": 1348,
  "source_repo": "SciDEX"
}